Tempus Announces Dr. Ezra Cohen as Chief Medical Officer of Oncology

Tempus, a leader in artificial intelligence and precision medicine, today announced that Ezra Cohen, MD is joining the company as its Chief Medical Officer of Oncology. Dr. Cohen is helping oversee Tempus’ medical operations, with a primary focus on oncology and the company’s patient and provider offerings. In this role, he is applying his deep clinical expertise to the delivery of Tempus’ AI-enabled precision medicine solutions to improve patient care.

Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.

“In the last few years, we have had the opportunity to develop a strong partnership with Dr. Cohen as we worked together to apply Tempus’ precision medicine solutions to his patients’ care,” said Eric Lefkofsky, Founder and CEO of Tempus. “Now as part of our team, we look forward to the insight and expertise he can bring to our efforts to improve patient outcomes and advance research in the field.”

“I have seen first-hand the impact that Tempus’ platform can have in helping physicians like myself deliver personalized patient care,” said Dr. Cohen. “I look forward to joining this talented team to drive its mission forward and revolutionize our approach to research and clinical care.”

Dr. Cohen earned his medical degree at University of Toronto and completed a hematology/oncology fellowship at the University of Chicago, where he was named chief fellow. He is board certified in medical oncology, and a fellow of the Royal College of Physicians and Surgeons of Canada (FRCPSC) and the American Society of Clinical Oncology (FASCO).

About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit

Related Content

View more
  • post image

    Tempus’ FDA approval and insights on the use of companion diagnostics in clinical development

    Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.

    In this webinar, you will hear how the Tempus platform can support development of new therapies by combining real-world data, next-generation sequencing, and artificial-intelligence to advance precision oncology. Our regulatory and scientific experts will provide an overview of the pathways for diagnostics and share best practices for biopharma and biotech sponsors to consider in clinical trial design and the development of companion diagnostics.

    Watch replay
  • post image

    Using TIME to accelerate trial enrollment for Aadi Bioscience

    The Tempus TIME program provided Aadi access to a network of providers and patients to accelerate enrollment for its PRECISION 1 TSC1/TSC2 phase 2 clinical trial. Read on to learn how the TIME program decreased time to enroll with the just-in-time activation of ~10 business days.

    Read more
  • post image

    Increasing PTS using multimodal data

    Learn how AstraZeneca employs multimodal data to increase the probability of technical success of all Phase 3 oncology studies.

    Watch replay